Therapeutic Area | MeSH |
---|---|
nervous system diseases | D009422 |
mental disorders | D001523 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ADDERALL XR 10 | Takeda | N-021303 RX | 2001-10-11 | 1 products, RLD |
ADDERALL XR 20 | Takeda | N-021303 RX | 2001-10-11 | 1 products, RLD |
ADDERALL XR 30 | Takeda | N-021303 RX | 2001-10-11 | 1 products, RLD, RS |
ADDERALL XR 25 | Takeda | N-021303 RX | 2002-05-22 | 1 products, RLD |
ADDERALL XR 5 | Takeda | N-021303 RX | 2002-05-22 | 1 products, RLD |
ADDERALL XR 15 | Takeda | N-021303 RX | 2002-05-22 | 1 products, RLD |
MYDAYIS | Takeda | N-022063 RX | 2017-06-20 | 4 products, RLD, RS |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
narcolepsy | EFO_0000614 | D009290 | G47.4 |
attention deficit disorder with hyperactivity | EFO_0003888 | D001289 | F90 |
Expiration | Code | ||
---|---|---|---|
AMPHETAMINE ASPARTATE / AMPHETAMINE SULFATE / DEXTROAMPHETAMINE SACCHARATE / DEXTROAMPHETAMINE SULFATE, MYDAYIS, TAKEDA PHARMS USA | |||
2023-03-13 | PED |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | 1 | — | — | — | 1 |
Drug common name | Dextroamphetamine saccharate |
INN | — |
Description | (S)-amphetamine is a 1-phenylpropan-2-amine that has S configuration. It has a role as a neurotoxin, an adrenergic uptake inhibitor, a dopaminergic agent, a sympathomimetic agent, a dopamine uptake inhibitor and an adrenergic agent. It is an enantiomer of a (R)-amphetamine. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | C[C@H](N)Cc1ccccc1.O=C(O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(=O)O |
PDB | — |
CAS-ID | 51-64-9 |
RxCUI | 3288 |
ChEMBL ID | CHEMBL3989844 |
ChEBI ID | — |
PubChem CID | 5826 |
DrugBank | DB01576 |
UNII ID | — |